Globe Newswire (Wed, 23-Sep 7:33 AM ET)
Globe Newswire (Wed, 16-Sep 7:30 AM ET)
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Tue, 8-Sep 9:00 AM ET)
Artelo Biosciences Announces Reverse Stock Split
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Globe Newswire (Thu, 20-Aug 8:52 AM ET)
Globe Newswire (Mon, 17-Aug 8:52 AM ET)
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Globe Newswire (Thu, 13-Aug 8:00 AM ET)
Globe Newswire (Mon, 10-Aug 8:47 AM ET)
Globe Newswire (Wed, 22-Jul 8:39 AM ET)
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Artelo Biosciences trades on the NASDAQ stock market under the symbol ARTL.
As of October 6, 2026, ARTL stock price declined to $3.46 with 55,620 million shares trading.
ARTL has a beta of -2.95, meaning it tends to be less sensitive to market movements. ARTL has a correlation of 0.07 to the broad based SPY ETF.
ARTL has a market cap of $1.90 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ARTL traded as high as $772.20 and as low as $3.41.
The top ETF exchange traded funds that ARTL belongs to (by Net Assets): VXF.
ARTL has underperformed the market in the last year with a price return of -97.3% while the SPY ETF gained +17.6%. ARTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -65.4% and -15.6%, respectively, while the SPY returned +4.9% and +0.7%, respectively.
ARTL support price is $3.10 and resistance is $3.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTL shares will trade within this expected range on the day.
